Our research projects are funded by the following federal agencies:
|
R01 In-utero exposure to psychotropic medications and the risk of neurodevelopmental disorder, 2018-2023, NIMH
|
|
R01 Safety of Benzodiazepines and Non-Benzodiazepine Sedative Hypnotics in Pregnancy, 2022-2027, NICHD
|
|
R01 The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy 2020-2023, NIDA |
We also conduct research sponsored by industry partners (e.g., Eli Lilly, GlaxoSmithKline).
Past Research Projects
|
K01 Improved methods to assess the comparative safety of new psychiatric medications, 2013-2018, NIMH
R01 Comparative safety of commonly prescribed psychotropic drugs in pregnant women, 2014-2017, NIMH |
|
R03 Ondansetron and risk of congenital malformations, 2017-2019, NICHD K08 Comparative safety and effectiveness of antihypertensives in pregnancy, 2013-2018, NICHD R21 Pregnancy registries nested in the international pooled health care databases, 2017-2019, NICHD R21 International Pooling Project to Study the Safety of Drugs in Pregnancy, 2017-2019, NICHD |
|
R01 The impact of prescription opioid use on pregnancy outcomes, 2017-2021, NIDA
|
|
R01 Comparative effectiveness and safety of depression treatments during pregnancy, 2009-2014, AHRQ
|
|
Developing the capability of using national Medicaid data for FDA post-marketing surveillance to assess medication safety during pregnancy, 2017-2019, FDA
|
